Navigation Links
Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer
Date:9/10/2009

3, 11%), anemia (Hb <10 g/dL, 58%; <8 g/dL, 16%), thrombocytopenia (<150,000 platelets/mm3, 61%), nausea (18%), asthenia (7%), fever (8%), alopecia (9%), vomiting (8%), diarrhea (5%), and stomatitis (5%)

Please visit www.doxil.com for the full Prescribing Information, including Boxed WARNINGS.

About Centocor Ortho Biotech Products, L.P.

Centocor Ortho Biotech redefines the standard of care in immunology, nephrology, and oncology. The company was formed when Centocor, Inc. and Ortho Biotech Products, L.P. were consolidated in late 2008, and was renamed Centocor Ortho Biotech. Built upon a pioneering history, Centocor Ortho Biotech harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Centocor Ortho Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates, and healthcare professionals have access to the latest treatment information, support services, and quality care.


'/>"/>
SOURCE Centocor Ortho Biotech Products, L.P.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
2. Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
3. Centocor/Janssen-Cilags Ustekinumab Will Become the Gold Standard for Psoriasis By 2011
4. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
5. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
6. GeneNews provides Centocor access to its osteoarthritis program
7. Baseline Research Indicates High Interest in Centocor-Ortho Biotechs SIMPONI(R)
8. Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
9. Centocor Ortho Biotech Inc. Awarded $1.67 Billion Patent Jury Verdict from Abbott Laboratories
10. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
11. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Charm Sciences, Inc. is pleased ... (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) ... Sciences to monitor aflatoxin in grains utilizing Charm’s ... FAST Aflatoxin Quantitative Test (solvent-based). , The Charm ... Water Extraction Technology to extract aflatoxin from the ...
(Date:5/21/2015)... May 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... company that develops and commercializes proprietary technologies and products ... operational results for the second fiscal quarter ended March ... Company continued to advance business with our existing customers ... , President and CEO of SQI. "The delivery of ...
(Date:5/21/2015)... , May 21, 2015  Susan Hedstrom, Executive ... a nonprofit organization dedicated to supporting research to ... (PWS), announced today that FPWR has received the ... Irina Shaulov contributed $1 million in support ... "Our gift ...
(Date:5/21/2015)...  The EveryLife Foundation for Rare Diseases applauded ... Amy Klobuchar (D-MN) today for introducing the ... or OPEN ACT. Supported by more ... bipartisan legislation promises to rapidly bring hundreds of ... patients by incentivizing drug makers to "repurpose" approved ...
Breaking Biology Technology:USDA-GIPSA (FGIS) Awards 5 Year Contract for Aflatoxin Tests to Charm Sciences 2SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2
... , , ATLANTA, Sept. ... Board: EAUI), a leading provider of electrolyzed water for high-volume, ... trial with a leading international beverage bottling company enabling the ... sanitation process for CIP (Clean-in-Place) applications. EAU,s electrolyzed water ...
... , ... Expressionist modules Refiner Array and Analyst deliver expanded processing and reporting functionalities. ... Basel, ... leading provider of in silico solutions for pharmaceutical R&D and related life sciences, ...
... , , , CLEVELAND, ... GanedenBC30(R) , today announced the launch of the first ... the latest in a number of innovative probiotic-enhanced products introduced by Ganeden ... recent popularity of thin strips as a supplement delivery system led Ganeden ...
Cached Biology Technology:EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 2EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 3EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application 4Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 2Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 3Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine 4Ganeden Biotech Introduces the First Probiotic Thin Strip 2Ganeden Biotech Introduces the First Probiotic Thin Strip 3
(Date:4/14/2015)...  HYPR Corp. today announced it has joined ... tm , an industry consortium transforming online authentication ... technology and collaborate to deliver open specifications for ... and private, and easier to use. ... sensitive user information and eliminates the dependency on ...
(Date:4/10/2015)... 10, 2015 Research and Markets ... "Security Competitive Profiles - NEC" report to ... NEC will continue to supply a range of ... with a company focus on the development of a ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... drugs currently studied in clinical trials appears to reduce ... at Georgetown University Medical Center report in an upcoming ... They say the results suggest that this class of ... been able to do-- prevent the long-term and continuing ...
... the specific biological mechanisms believed to lead to ... Diamond Blackfan anemia (DBA). Scientists say with further ... to current thinking about treatment for this disease ... George Thomas, PhD, Stefano Fumagalli, PhD, ...
... or ,gloopiness, of different parts of cancer cells increases ... according to new images that provide fundamental insights into ... today (15 March). The ... cells whilst they are dying as a result of ...
Cached Biology News:Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 2Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 3Cellular discovery may lead to targeted treatment for rare form of anemia 2Cellular discovery may lead to targeted treatment for rare form of anemia 3A sticky business -- how cancer cells become more 'gloopy' as they die 2
Anti-human CD48/BLAST-1, clone MEM102, Monoclonal Antibody...
Raf-1 (C-12)-G...
... DuoSet ELISA Development kit contains the basic ... ELISAs to measure natural and recombinant mouse ... and serum. Each kit contains sufficient materials ... plates, provided that the following conditions are ...
E1A (adenovirus early region 1)...
Biology Products: